Introduction {#Sec1}
============

Lesinurad is a selective uric acid reabsorption inhibitor (SURI) medication that was recently approved by the European Commission following a positive evaluation from the European Medicines Agency (EMA) of the European Union and the United States Food and Drug Administration (FDA) \[[@CR1]\]. Lesinurad exerts its urate-lowering action by selectively inhibiting urate transporters (principally URAT-1 and OAT-4) in the proximal renal tubule and blocking uric acid reabsorption, thereby increasing net uric acid renal excretion \[[@CR2]\].

The safety profile panel established during the clinical development of lesinurad included renal events, as would be expected for any uricosuric medication. Renal events were classified as increases in serum creatinine (sCr) concentrations above baseline, renal failure (which encompassed a broad range of events, including acute or chronic renal failure and acute pre-renal failure), or nephrolithiasis. Renal events, and specifically increases in sCr concentration, were more frequent in patients on lesinurad than in those on a placebo (PBO), with a dose-dependent relationship \[[@CR3]\], and these events were more common in patients who did not receive a xanthine oxidase inhibitor (XOI) while on lesinurad therapy \[[@CR4]\] and in those with moderate kidney impairment \[[@CR5]\]. These findings led the EMA and FDA to approve lesinurad only when used in combination with a XOI and at a dose of 200 mg/day, and to recommended that it should/must not be initiated in patients with an estimated glomerular filtration rate (eGFR) below 45 mL/min/1.73 m^2^ (summary of product characteristics or SmPC, FDA) \[[@CR6]\] or 30 mL/min/1.73 m^2^ (SmPC, EU) \[[@CR7]\] per minute.

Intriguingly and importantly, even though elevations in sCR were more common in lesinurad-treated patients than in those receiving a placebo, the incidence rates of renal failure and renal nephrolithiasis did not differ between these groups, although patients with a previous history of renal lithiasis were not excluded \[[@CR8]\]. While several hypotheses have been proposed for the development of elevated sCR in lesinurad-treated patients, there is no widely accepted explanation for this occurrence. Consequently, recommendations are lacking in risk assessments of patients who may be at risk of adverse renal events when treated with lesinurad combination therapy.

Our objective was to reassess the relative risks of various adverse renal events in lesinurad-treated patients from three pivotal placebo-controlled combination clinical trials stratified according to renal function; to review, critique, and attempt to explain the results; and to propose monitoring strategies.

Methods {#Sec2}
=======

We analyzed data from three major phase 3 clinical trials that tested the efficacy and safety of lesinurad in clinical practice. Incidence rates of adverse renal events were derived from Tables 2 and 3 in the full prescribing information for Zurampic \[[@CR6]\].

Table 2 of the prescribing information shows data on the incidence rates of adverse renal events in all three major placebo-controlled clinical studies (CLEAR 1, CLEAR2, and CRYSTAL) in which lesinurad in combination with a XOI (either allopurinol or febuxostat) was compared with XOI alone \[[@CR9]--[@CR11]\]. Adverse renal events were defined as follows: (1) increased blood creatinine, defined as a greater than 1.5-fold increase in sCr as compared to the baseline measurement at trial entry; (2) renal failure (a composite term that described any occurrence of acute or chronic renal failure and acute prerenal failure); and (3) nephrolithiasis. The three studies together provided 516, 511, and 510 patients in the XOI + PBO, XOI + lesinurad 200 mg/day, and XOI + lesinurad 400 mg/day groups, respectively.

Table 3 of the SmPC for Zurampic includes data on the occurrence of adverse events in all three clinical trials according to study arm (XOI + PBO, *n* = 510; XOI + lesinurad 200 mg/day, *n* = 509; and XOI + lesinurad 400 mg/day, *n* = 508) and stratified by baseline renal function category (≥ 90, ≥ 60 to \< 90, ≥ 30 to \< 60 mL/min/1.73 m^2^).

Statistical Analysis {#Sec3}
--------------------

We determined the patient-year exposure for each study arm from a recently published report on the safety of lesinurad \[[@CR3]\] as 408, 396, and 390 patient-years, respectively. These values were then used to compute the incidence rate of each adverse renal event stratified by GFR category (≥ 90 mL/min, ≥ 60 to \< 90 mL/min, ≥ 30 to \< 60 mL/min/1.73 m^2^) in each treatment arm.

Risk ratios (RRs) and numbers needed to treat (NNTs) were calculated to determine the impact of each treatment on the rates of each specified adverse renal event. Harm was defined as RR \> 1 and benefit as RR \< 1. Calculations were performed using the MedCalc software (Medcalc Software bvba, Ostend, Belgium, <https://www.medcalc.org/calc/relative_risk.php>). These analyses were repeated to determine the RRs of adverse renal events stratified by kidney function. When the RR for a study cannot be calculated because there are no events in the control group of a study and the standard errors cannot be computed, it is customary to add 0.5 to each cell of the 2 × 2 contingency table \[[@CR12]\].

Compliance with Ethics Guidelines {#Sec4}
---------------------------------

Data were retrieved from a public resource: the full prescribing information for Zurampic. This article does not contain any studies with human participants or animals performed by any of the authors.

Results {#Sec5}
=======

The incidence of increased sCr was numerically higher among patients allocated to LES 200 mg daily than among patients allocated to a placebo (4.3% vs. 2.3% respectively). The corresponding RR (1.85, 0.93--3.70) was not statistically significant (Table [1](#Tab1){ref-type="table"}). In contrast, patients allocated to the LES 400 mg dose showed a significantly higher incidence of increased sCR than patients on a placebo, along with a statistically significant RR of 3.37 (1.79--6.35) (Table [1](#Tab1){ref-type="table"}).Table 1Overall incidence rates of adverse renal events in phase III clinical trials comparing lesinurad plus XOI to placebo plus XOIXOI + PBO\
*N* = 516XOI + LES200 \
*N* = 511RR (95% CI)NNT*p*Events (%)Events (%)Increased sCr12 (2.3)22 (4.3)1.85 (0.93--3.70)− 510.081Renal failure11 (2.1)6 (1.2)0.55 (0.20--1.48)+ 1040.236Nephrolithiasis9 (1.7)3 (0.6)0.34 (0.09--1.24)+ 860.101XOI + PBO\
*N* = 516XOI + LES400\
*N* = 510RR (95% CI)NNT*p*Events (%)Events (%)Increased sCr12 (2.3)40 (7.8)3.37 (1.79--6.35)− 18\< 0.000Renal failure11 (2.1)18 (3.5)1.65 (0.79--3.47)− 720.182Nephrolithiasis9 (1.7)13 (2.5)1.46 (0.63--3.39)− 1240.377*Increased sCr* serum creatinine \> 1.5 × baseline value, *RR* relative risk or risk ratio (absolute risk of an event in the active group/absolute risk for event in the control group), *NNT* number needed to treat (− for harm, + for benefit), *XOI* xanthine oxidase inhibitor, *PBO* placebo, *LES200* lesinurad 200 mg once a day, *LES400* lesinurad 400 mg once a day

On the other hand, the incidence rates for renal failure and nephrolithiasis were numerically lower for the 200 mg daily dose vs. PBO, but this was not a statistically significant difference. Similarly, patients allocated to the LES 400 mg dose experienced rates of renal failure and nephrolithiasis that were not significantly different from those in the placebo arm (Table [1](#Tab1){ref-type="table"}). The analysis of adverse renal events according to eGFR category is presented in Table [2](#Tab2){ref-type="table"}. For each GFR category, the rate of increased sCR was numerically higher for the LES 200 mg group than for the placebo arm (3.0, 3.8, and 6.9 vs. 0.6, 1.7, and 5.9 for patients in the categories CrCl ≥ 90, CrCl ≥ 60 to ≤ 90, and CrCl ≥ 30 to ≤ 60 mL/min, respectively) but there were no statistically significant differences. Intriguingly, the RR of increased sCR decreased with worsening GFR, from 5.34 for patients with CrCl ≥ 90 mL/min to 1.17 for patients with CrCl ≥ 30 to ≤ 60 mL/min; the number needed to treat was over 100 for the latter group. Furthermore, analysis of the RR of renal failure revealed a similar pattern, with the RR decreasing from 6.30 in patients with CrCl ≥ 90 mL/min to 0.40 for patients with CrCl ≥ 30 to ≤ 60 mL/min. The RR of renal failure for the LES 200 mg group versus the placebo group was not statistically significant.Table 2Analysis of adverse renal events in patients stratified by estimated glomerular filtration rateCrCl ≥ 90 mL/minXOI + PBO\
*N* = 510XOI + LES200\
*N* = 509RR (95% CI)NNT*p*Events (%)\
*N* = 180Events (%)\
*N* = 200Increased sCr1 (0.6)6 (3.0)5.34 (0.65--43.98)− 410.199Renal failure03 (1.5)6.30 (0.32--121.21)− 290.222CrCl ≥ 60 to \< 90 mL/minXOI + PBO\
*N* = 510XOI + LES200\
*N* = 509RR (95% CI)NNT*p*Events (%)\
*N* = 229Events (%)\
*N* = 208Increased sCr4 (1.7)8 (3.8)2.20 (0.67--7.21)− 480.192Renal failure4 (1.7)1 (0.5)0.28 (0.03--2.44)+ 790.247CrCl ≥ 30 to \< 60 mL/minXOI + PBO\
*N* = 510XOI + LES200\
*N* = 509RR (95% CI)NNT*p*Events (%)\
*N* = 101Events (%)\
*N* = 101Increased sCr6 (5.9)7 (6.9)1.17 (0.40--3.35)− 1010.775Renal failure5 (5.0)2 (2.0)0.40 (0.08--2.01)+ 490.267CrCl ≥ 90 mL/minXOI + PBO\
*N* = 510XOI + LES400\
*N* = 508RR (95% CI)NNT*p*Events (%)\
*N* = 180Events (%)\
*N* = 203Increased sCr1 (0.6)12 (5.9)10.64 (1.40--81.03)− 190.022Renal failure07 (3.4)13.31 (0.76--231.40)− 290.0756CrCl ≥ 60 to \< 90 mL/minXOI + PBO\
*N* = 510XOI + LES400\
*N* = 508RR (95% CI)NNT*p*Events (%)\
*N* = 229Events (%)\
*N* = 213Increased sCr4 (1.7)21 (9.9)5.64 (1.97--16.18)− 120.001Renal failure4 (1.7)7 (3.3)1.88 (0.59--6.34)− 650.308CrCl ≥ 30 to \< 60 mL/minXOI + PBO\
*N* = 510XOI + LES400\
*N* = 508RR (95% CI)NNT*p*Events (%)\
*N* = 101Events (%)\
*N* = 92Increased sCr6 (5.9)10 (10.9)1.83 (0.69--4.84)− 200.223Renal failure5 (5.0)7 (4.2)0.87 (0.24--3.17)− 1660.843*CrCl* creatinine clearance, *Increased sCr* serum creatinine more than 1.5 × baseline value, *RR* relative risk or risk ratio (absolute risk for the event in the active group/absolute risk for the event in the control group), *NNT* number needed to treat (− for harm, + for benefit), *XOI* xanthine oxidase inhibitor, *PBO* placebo, *LES200* lesinurad 200 mg once a day, *LES400* lesinurad 400 mg once a day

Compared to the placebo group, patients treated with XOI plus LES 400 mg daily presented significantly higher incidence rates of increased sCR (5.9, 9.9, and 10.9 vs. 0.6, 1.7, and 5.9 for patients in the categories CrCl ≥ 90 mL, CrCl ≥ 60 to ≤ 90, and CrCl ≥ 30 to ≤ 60 mL/min, respectively). Differences between groups did not reach statistical significance in the lower estimated glomerular filtration rate strata, as the magnitude of the risk ratio decreased with worsening GFR, from 10.64 (1.40--81.03) to 5.64 (1.97--16.18) to 1.83 (0.69--4.84). A similar pattern was observed for renal failure. Figure [1](#Fig1){ref-type="fig"} provides a visual representation of the incidence of increased sCR and the corresponding risk ratio for each treatment allocation stratified by GFR category.Fig. 1Plot showing that the incidence rate of increased serum creatinine increased with decreasing eGFR, but that the RR decreased with decreasing eGFR (because the incidence rate of increased serum creatinine increases more rapidly with decreasing eGFR in the PBO arm than in the LES arms). *RR* relative risk, *PBO* placebo, *LES* lesinurad

Discussion {#Sec6}
==========

Using data released publicly for use by healthcare providers \[[@CR6]\], this analysis found that the rate of adverse renal events was not significantly different for the LES 200 mg group and the placebo group. While the incidence of increased sCR showed a modest increase for the LES 200 mg group as compared to the placebo group, the incidence rates of renal outcomes other than increased serum creatinine (sCri: renal failure and nephrolithiasis) were numerically lower for the LES 200 mg arm than for the placebo arm, with none of these differences between groups being statistically significant. In contrast, treatment with the higher LES 400 mg dose yielded significantly higher rates of increased sCR compared to the placebo group, but---surprisingly---no significantly increased risk of renal failure of nephrolithiasis. In general, adverse renal event rates were lowest among patients with normal renal function rather than among those with decreased GFR. However, we observed that the rate of adverse renal events with increased sCR rose at a faster rate in the placebo arm than in the LES 200 mg and 400 mg arms with worsening GFR, leading to a reduction in the relative risk.

It should be noted that while the elevation of serum creatinine from the baseline was measured as part of a safety analysis performed by the sponsor, clinical diagnoses were made by the investigators and compiled using predefined preferred terms to compile renal safety reports and included as supplemental material in \[[@CR3]\]. Another limitation inherent to this analysis is that it is not a meta-analysis. While such a meta-analysis including five clinical trials was recently reported \[[@CR13]\], it did not provide any fresh perspective on the optimal clinical approach to the safety of lesinurad or insight into pathophysiological mechanisms. Another limitation of our study is the fact that we could only use publicly available data compiled from phase 3 trials, and that the number of events was small.

Therefore, to evaluate the risk of adverse renal events between the placebo and active arms, we employed the relative risk or risk ratio, as recommended by the Cochrane collaboration to evaluate interventions \[[@CR12]\]. Patient-year exposure was similar for all groups, as was the number of patients allocated to each group, thus facilitating unbiased estimates.

In each analysis, we found that the RRs for LES 200 mg vs. placebo and LES 400 mg vs placebo decreased substantially with worsening kidney function, suggesting that the risk of adverse renal events diminished or was eliminated in patients with moderate kidney impairment. If lesinurad exhibited direct nephrotoxicity \[[@CR5]\], an increased risk of adverse events in patients with the worst kidney function would be expected, as happens with NSAIDs \[[@CR14]\]. In contrast, we observed a pattern of decreasing relative risk of adverse renal events with decreasing eGFR, suggesting that chronic kidney disease (CKD) is associated with pathophysiological changes that may protect against any potential nephrotoxicity associated with lesinurad/XOI combinations. By contrast, the US \[[@CR6]\] and EU \[[@CR7]\] recommend either not prescribing in some patients with moderate renal impairment (GFR \< 45 ml/min) or taking special precautions if it is prescribed, respectively.

Risk factors for adverse renal events associated with the use of uricosuric medications include the filtered load of uric acid (the product of the serum urate concentration × GFR), urinary pH (related to the acidification capacity), and urinary acid concentration (related to the concentration capacity). Indeed, higher clearance of uric acid (associated with better renal function) and undissociated urinary urate (related to both acidic urinary pH and the urinary uric acid concentration) have both been associated with an increased risk of nephrolithiasis during uricosuric treatment in monotherapy \[[@CR15]\]. Moreover, the appearance of altered urine sediment, namely the presence of red cells, while starting uricosuric medications was also associated with increased urine density and urinary creatinine and uric acid concentrations \[[@CR16]\]. Patients with significant CKD have reduced eGFR, a reduced capacity to concentrate urine, and a decreased capacity to acidify urine \[[@CR17], so they should benefit from a collective reduction in major risk factors for urate-induced adverse events. Moreover, the concomitant use of a XOI with lesinurad reduces the serum urate concentration and therefore the filtered load of uric acid in the glomerulus \[[@CR18]\].

Although not derived from this analysis, our empirical approach as precticing clinicians to the renal safety of lesinurad treatment---until further and specifically derived evidence is available---is to encourage adherence to the XOI treatment when used in combination with lesinurad, to ensure that adequate fluid intake is maintained, initial evaluation followed by regular surveillance or renal function is untertaken at least using spot urine samples for analysis including abnormals, uric acid, creatinine, density, and pH for all patients, as we used to do with other uricosurics.

Conclusions {#Sec7}
===========

The rate of adverse renal events was similar in the placebo and lesinurad 200 mg groups, while the rates of renal failure and nephrolithiasis were numerically lower in the lesinurad 200 mg group than in the placebo group. The risk ratio of sCri with lesinurad versus placebo decreased with worsening renal function.
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